Obesity in the GLP-1 Era: Clinical Characteristics and Prescribing Patterns in a Large Integrated Health System
Authors:
- Brian J. WellsBWBrian J. Wells
- Kristin M. LenoirKLKristin M. Lenoir
- Michael Webster-ClarkMWMichael Webster-Clark
- Nicholas M. PajewskiNPNicholas M. Pajewski
- Amanda T. Pons-JunkinsAPAmanda T. Pons-Junkins
- Michelle M. MielkeMMMichelle M. Mielke
- 14 November 2026
- journal article
- Published by Elsevier in Obesity Medicine
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Muscle loss and GLP-1R agonists useActa Diabetologica, 2025
- GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromesActa Diabetologica, 2025
- Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and IndicationJAMA Health Forum, 2025
- Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic StatusJournal of General Internal Medicine, 2025
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the USJAMA, 2025
- Once-Weekly Semaglutide in Adults With Alcohol Use DisorderJAMA Psychiatry, 2025
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or ObesityJAMA Network Open, 2025
- Pragmatic Implementation of Online Obesity Treatment and Maintenance Interventions in Primary CareJAMA Internal Medicine, 2024
- Clinical, economic, and health‐related quality of life outcomes in patients with overweight or obesity in the United States: 2016–2018Obesity Science & Practice, 2023
- Effect of an Online Weight Management Program Integrated With Population Health Management on Weight ChangeJAMA, 2020